Related Experiment Video
Updated: Jan 29, 2026

Intra-Peritoneal Transplantation for Generating Acute Myeloid Leukemia in Mice
Published on: January 6, 2023
Current challenges for CAR T-cell therapy of acute myeloid leukemia
Tim Sauer1, Cliona M Rooney1,2,3,4
1Center for Cell and Gene Therapy, Texas Children's Hospital, Houston Methodist Hospital, and Baylor College of Medicine, Houston, Texas.
Abstract:
KEY IDEAS Chimeric antigen receptor (CAR) T-cell therapy has the potential to improve the dismal outcome of patients diagnosed with acute myeloid leukemia (AML). A major challenge for CAR T-cell therapy of AML patients is identifying leukemia-specific target antigens. Immune escape through down-regulation of target antigens and/or a suppressive tumor microenvironment jeopardizes the success of CAR T-cell therapy.
Insights
Chimeric antigen receptor (CAR) T-cell therapy shows promise for acute myeloid leukemia (AML). Identifying specific targets and overcoming immune escape are key challenges for successful CAR T-cell treatment in AML patients.
Area of Science:
- Immunotherapy
- Hematologic Malignancies
- Cellular Therapy
Background:
- Acute myeloid leukemia (AML) has a poor prognosis, necessitating novel therapeutic strategies.
- Chimeric antigen receptor (CAR) T-cell therapy offers a promising avenue for treating AML.
- A significant hurdle in CAR T-cell therapy for AML is the identification of suitable leukemia-specific antigens.
Purpose of the Study:
- To highlight the potential of CAR T-cell therapy in improving outcomes for AML patients.
- To identify the critical challenges hindering the efficacy of CAR T-cell therapy in AML.
- To discuss strategies for overcoming immune escape mechanisms in CAR T-cell therapy for AML.
Main Methods:
- Review of current literature on CAR T-cell therapy for AML.
- Analysis of antigen identification strategies for leukemia-specific targets.
- Examination of immune escape mechanisms, including antigen downregulation and tumor microenvironment suppression.
Main Results:
- CAR T-cell therapy holds significant potential for AML treatment.
- Lack of specific leukemia targets and immune evasion limit therapeutic success.
- Downregulation of target antigens and a suppressive tumor microenvironment are major obstacles.
Conclusions:
- Target antigen identification is crucial for effective CAR T-cell therapy in AML.
- Overcoming immune escape mechanisms is essential for durable responses.
- Further research is needed to optimize CAR T-cell therapy for AML patients.
More Related Videos
Related Concept Videos
Differentiation of Common Myeloid Progenitor Cells
Gene Therapy
Electrical Current
Stem Cell Therapy for Tissue Regeneration
Types of Stem Cells used in Stem Cell Therapy
The two main cell...
Group Therapy
Current Density

